Pfizer, Arvinas and breast cancer

Pfizer-Arvinas' breast cancer treatment shows mixed results in late-stage study
Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of patients in a late-stage trial, sending the Connecticut-based biotech's shares down 36% before the bell.
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend progression-free survival (PFS) in certain patients in a Phase III trial.
Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy (update)
Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.
Pfizer-Arvinas' breast cancer treatment cuts progression for some patients in study
An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically significant results in others in a late-stage study.
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.
Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators
Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...
Posts falsely claim Pfizer published list of Covid-19 vaccine side effects
Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...
STAT1d
Telehealth platforms in senators’ crosshairs over relationship with Eli Lilly, Pfizer
Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.
Moderna suffers setback in vaccine patent battle with Pfizer
Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...
C&EN3d
Pfizer readies its next-generation COVID-19 antiviral
An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
Pfizer: Undervalued Safe Haven In Risk-Off Market
Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...
Zacks Investment Research on MSN4h
Pfizer (PFE) Stock Moves -0.43%: What You Should Know
The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...